Univariate analysis indicated that high peritumoral CD8+ T cells (p = 0.048; OR = 2.080, 95% CI: 1.005–4.305), low peritumoral Foxp3+ T cells (p = 0.015; OR = 0.400, 95% CI: 0.192–0.834), together with FIGO stage (p = 0.083; OR = 0.520, 95% CI: 0.248–1.089), lymph node metastases (p = 0.098; OR = 0.444, 95% CI: 0.170–1.161) were significantly correlated with clinical effectiveness. The gene discussed is FOXP3; the disease is metastatic malignant neoplasm in the lymph nodes.